Novavax, Inc. (NASDAQ:NVAX) Q1 2026 Earnings Call Transcript
James Kelly: Good morning, and thank you for joining us today to discuss our first quarter 2026 financial results and operational highlights.
Novavax Inc (NVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Shah Capital Management Himanshu H. Shah | 14,845,097 | $120,839,090 | +2% | 23.18% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 673,120 | $5,479,197 | 0.04% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 7,864 | $64,013 | -46% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | $6,500.00 | 14,473 | 2023-03-10 | Filing | |
| $7.04 | 2,000 | $14,088.00 | 13,473 | 2023-03-07 | Filing | |
| $7.48 | 3,000 | $22,453.50 | 11,473 | 2023-03-06 | Filing | |
| $139.64 | 700 | $97,748.00 | 2,800 | 2021-05-19 | Filing | |
| $48.83 | 1,500 | $73,245.00 | 1,500 | 2020-06-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.02 | 4,150 | $37,435.08 | 14,770 | 2024-12-13 | Filing | |
| $8.00 | 5,400 | $43,200.00 | 51,760 | 2024-12-31 | Filing | |
| $8.48 | 4,600 | $39,008.00 | 57,160 | 2024-12-24 | Filing | |
| $14.09 | 7,500 | $105,675.00 | 61,760 | 2024-06-21 | Filing | |
| $14.28 | 1,107 | $15,807.96 | 69,260 | 2024-06-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,151,625 | $58,214,228 | 0% | |
| 2. | 7,130,147 | $58,039,397 | 0% | |
| 3. | 6,880,481 | $56,007,115 | 16.67% | |
| 4. | 4,477,701 | $36,448,486 | 0.01% | |
| 5. | 1,390,565 | $11,319,201 | 2.76% |
News See All
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now?
Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on NVAX.
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead
TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy rating.
9 Most Undervalued Healthcare Stocks to Buy Now
On April 17, Matt Powers, managing partner at Powers Advisory Group, appeared on CNBC’s Squawk Box to discuss the forces shaping current market behavior.
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Novavax's Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Conference Call.
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets
TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating.
9 High Growth Small Cap Stocks That Are Profitable
As strategists weigh solid earnings momentum against expensive valuations and longer-term dangers, market opinions are still divided.
Novavax, Inc. (NVAX): A Bull Case Theory
We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NVAX.
Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.